Technical Data
B2553-32
Bone Morphogenetic Protein 7 (BMP7, OP-1, Osteogenic Protein-1) Human, Recombinant
2ug
10ug
10ug
|
Technical Data |
|
B2553-32 |
Bone Morphogenetic Protein 7 (BMP7, OP-1, Osteogenic Protein-1) Human, Recombinant |
2ug 10ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: RT |
|
BMP-7 (osteogenic protein 1) belongs to the Bone-growth regulatory factors that are members of the transforming growth factor-beta (TGF-beta) superfamily of proteins. They are synthesized as large precursor molecules which are cleaved by proteolytic enzymes. The active form can consist of a dimer of two identical proteins or a heterodimer of two related bone morphogenetic proteins. Recombinant Human BMP-7 is a monomeric, non-glycosylated, Polypeptide chain containing 139 amino acids and having a molecular mass of 15.68kD. Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Thr-Gly-Ser-Lys. Applications: Suitable for use in Western Blot, ELISA, preparing antibodies for BMP-7 monomer and as a molecule standard in detecting secreted BMP-7 in reduced SDS-PAGE. Other applications not tested. Storage and Stability: Lyophilized powder may be stored at -20°C. Reconstitute with sterile 20mM acetic acid. Aliquot and store at -20°C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer with 0.1% HSA or BSA. Molecular Weight: 15.68kD |
Source: Recombinant, Human (E. coli). Purity: 95% by RP-HPLC or SDS-PAGE. Chromatographically purified.Chromatographically purified. Endotoxin: 0.1ng/ug (IEU/ug) Concentration: ~1mg/ml Form: Supplied as a lyophilized powder in 10mM sodium citrate, pH 3.5. Reconstitute with sterile 20mM acetic acid to 0.1mg/ml. This solution can then be diluted into other aqueous solutions with 0.1% HSA or BSA. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Sinus floor augmentation with simultaneous placement of dental implants in the presence of platelet-rich plasma or recombinant human bone morphogenetic protein-7. Roldan JC, Jepsen S, Knuppel H, Clin Oral Implants Res 2004 Dec;15(6):716-23 2. Histological assessment of bioengineered new bone in repairing osteoperiosteal mandibular defects in sheep using recombinant human bone morphogenetic protein-7. Abu-Serriah MM, Odell E, Gillar A, Br J Oral Maxillofac Surg 2004 Oct;42(5):410-8 3. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Li T, Surendran K, Mathew S, Curr Opin Nephrol Hypertens 2004 Jul;13(4):417-22 4. Bone morphogenetic protein-7 from serum of pregnant mice is available to the fetus through placental transfer during early stages of development. Borovecki F, Jelic M, Sampath KT, Nephron Exp Nephrol 2004;97(1):e26-32 5. Are recombinant human bone morphogenetic protein-7 and tobramycin compatible? An experiment in rats. Kawaguchi AT, Reddi AH, Yinger KE, J Orthop Trauma 2004 Apr;18(4):225-32 6. Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. Wang S, Hirschberg R, J Biol Chem 2004 May 28;279(22):23200-6
|
||